Accelerating The Next Generation of Life Sciences

Innovation-driven biotechnology company focusing
on the creation and commercialization of healthcare solutions
to make a difference

MATLOC

MATLOC 1 is point of care, lab on chip digital device currently under development for screening of individuals at risk for the development of Chronic Kidney Disease

MATLOC I is based on proprietary lab-on-chip technology allowing advanced biological sample processing and analysis in miniaturized microfluidic channels while allowing transfer of data to your mobile phone.

MATLOC 1 is not yet approved for use in the US.

DuraGraft

  • DuraGraft®- Marizyme’ s flagship product is a first-in-class product used during Coronary Artery Bypass Grafting (CABG surgery) to help prevent vein graft failure and its complications.
  • DuraGraft® is a biocompatible intraoperative vascular graft storage and flushing solution that maintains the graft’s endothelial function and structure by preventing ischemic injury
  • DuraGraft has been evaluated extensively in clinical studies/registries and is approved for use in Europe and indicated for use during the harvesting and grafting interval of vascular surgery as a treatment to maintain structural and functional integrity of vascular conduits.  DuraGraft reduces the incidence of complications associated with graft failure by maintaining normal graft function.

DuraGraft is CE approved for use in the EU and in ex-US countries. DuraGraft is not yet FDA approved in the US.

Krillase

Krillase- Extract of Antarctic Krill comprised of a complex of several proteases that are highly active over a wide temperature range.  The activity of Krillase at low temperatures offers distinct advantages over other enzymes typically used in the isolation of cells from tissues and organs.

Krillase has been shown to be active in the removal or biofilm from soft and hard tissues, and has applications in wound debridement/skin grafting.

Krillase-based products are currently under development for the veterinary market for plaque reduction in dogs and cats.

Krillase is not yet approved for use in the US.

  • DuraGraft®- Marizyme’ s flagship product is a first-in-class product used during Coronary Artery Bypass Grafting (CABG surgery) to help prevent vein graft failure and its complications.
  • DuraGraft® is a biocompatible intraoperative vascular graft storage and flushing solution that maintains the graft’s endothelial function and structure by preventing ischemic injury
  • DuraGraft has been evaluated extensively in clinical studies/registries and is approved for use in Europe and indicated for use during the harvesting and grafting interval of vascular surgery as a treatment to maintain structural and functional integrity of vascular conduits.  DuraGraft reduces the incidence of complications associated with graft failure by maintaining normal graft function.

DuraGraft is CE approved for use in the EU and in ex-US countries. DuraGraft is not yet FDA approved in the US.

MATLOC 1 is point of care, lab on chip digital device currently under development for screening of individuals at risk for the development of Chronic Kidney Disease

MATLOC I is based on proprietary lab-on-chip technology allowing advanced biological sample processing and analysis in miniaturized microfluidic channels while allowing transfer of data to your mobile phone.

MATLOC 1 is not yet approved for use in the US.

Krillase- Extract of Antarctic Krill comprised of a complex of several proteases that are highly active over a wide temperature range.  The activity of Krillase at low temperatures offers distinct advantages over other enzymes typically used in the isolation of cells from tissues and organs.

Krillase has been shown to be active in the removal or biofilm from soft and hard tissues, and has applications in wound debridement/skin grafting.

Krillase-based products are currently under development for the veterinary market for plaque reduction in dogs and cats.

Krillase is not yet approved for use in the US.

Why should you choose Marizyme?

With a series of multiple acquisitions in the past, Marizyme has been successful in developing a diverse life science portfolio – DuraGraft, MATLOC, and Krillase.

Chronic Kidney Disease (CKD) Screening
Pet Health

The ultimate goal of our company is the acquisition, development, and commercialization of medical device technologies that enhances patient care and minimizes cost to the healthcare systems.

CABG & Peripheral Bypass Surgery
Fat Grafting (Pipeline)
Trailblazers in the global biotechnology market

Duragraft reduces
graft failure

Get In Touch With Us

Fill in your details to get in touch with our spokesperson

    Popular Medical Services

    Benefit For Physical Mental
    and Virtual Care

    Making A Difference

    How This Multi-Technology Platform Is Improving Lives?

    With more than 800K heart bypass (CABG) procedures being performed worldwide, it becomes increasingly important to reduce the complications of graft failures. Apart from that, globally, 37 million people are estimated to have CKD with over 80 million at significant risk of the same. Marizyme’s multi-technology platform provides not only provides a low-cost solution but aids in the detection of these diseases at an early stage.

    Estimated savings in implementation when using Mobile Health Clinics
    Supports referrals to provider networks and care management pr
    Our Testimonials

    What Our Patients Say About Our Medical

    Strategic Partnerships

    We have more than 23000 k+
    Trusted Business Customers
    300 +
    Professional Doctors
    1 K +
    Saticfied Our Clients
    800 +
    Win International Awards
    1 K +
    4.9 Star Reviews